News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lightlake Therapeutics Inc. (LLTP) Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting



3/27/2013 11:15:20 AM

LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. ( OTCBB: LLTP) (the “Company” or “Lightlake”), an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company’s Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED) has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES